Company news
Proteomics International Laboratories Ltd. (ASX:PIQ) news
Proteomics International Laboratories Ltd. news releases on 6ix. Latest, Jun 30, 2022: Endometriosis clinical validation study readout positive
Press releases — page 3
Endometriosis clinical validation study readout positive
June 29, 2022
Proteomics secures licence to oesophageal cancer biomarkers
June 20, 2022
PromarkerD manufacturing tech-transfer completed
June 15, 2022
Proteomics awarded $400,000 funding to support manufacturing
May 11, 2022
March 2022 Quarterly Activities Report and Appendix 4C
April 27, 2022
New Clinical Advisory Board for PromarkerD global rollout
April 12, 2022
PromarkerD completes pre-assessment for Medicare rebate
February 21, 2022
Unique panel of biomarkers identified for oesophageal cancer
February 3, 2022
December 2021 Quarterly Activities Report and Appendix 4C
January 26, 2022
Proteomics secures major pharmacokinetic testing contract
December 15, 2021
Proteomics receives $1.2 million in R&D tax incentive
December 13, 2021
PromarkerD distribution network expands to Britain
November 22, 2021
PromarkerD outperforms standard of care tests for DKD
November 4, 2021
Proteomics awarded $100,000 manufacturing funding
November 2, 2021
September 2021 Quarterly Activities Report and Appendix 4C
October 27, 2021
Clinical utility study shows benefit of PromarkerD testing
October 17, 2021
Proteomics contracts Biotem to manufacture PromarkerD kits
August 11, 2021
Proteomics to collaborate to validate test for endometriosis
August 3, 2021
June 2021 Quarterly Activities Report and Appendix 4C
July 29, 2021
Proteomics engages Abcam to manufacture PromarkerD reagents
July 21, 2021
Study shows diabetes drug improves PromarkerD risk scores
July 15, 2021
Reinstatement to Official Quotation
July 2, 2021
Suspension from Official Quotation
June 29, 2021
Modelling shows PromarkerD could save US payers $384 billion
June 24, 2021
Proteomics secures major analytical services contract
May 17, 2021
Major economic health benefit demonstrated for PromarkerD
May 12, 2021
March 2021 Quarterly Activities Report and Appendix 4C
April 28, 2021
ISO 13485 certification received - Manufacturing Update
April 22, 2021
Response to Price Query
February 16, 2021
Proteomics International seeks FDA approval for PromarkerD
February 7, 2021
December 2020 Quarterly Activities Report and Appendix 4C
January 27, 2021
AGM Investor Presentation
November 25, 2020
Middle East is next market for PromarkerD immunoassay test
November 11, 2020
PromarkerD clinical assay performance results published
November 4, 2020
Proteomics receives $1.1 million in R&D tax incentive
November 2, 2020
Completion of Placement and Appendix 2A
November 1, 2020
September 2020 Quarterly Activities Report and Appendix 4C
October 27, 2020
Proteomics International raises $6m in successful Placement
October 22, 2020
First distribution agreement for PromarkerD immunoassay
October 15, 2020
Partnership with QIMR Berghofer targets oesophageal cancer
October 8, 2020
June 2020 Quarterly Activities Report and Appendix 4C
July 28, 2020
PromarkerD Intellectual Property portfolio expands
July 27, 2020
Appendix 3Y - Directors on-market purchase of shares
June 28, 2020
Big pharma clinical study validates PromarkerD kidney test
June 14, 2020
Updated Investor Presentation
June 9, 2020
Proteomics International receives COVID-19 research grants
May 25, 2020
Appendix 4C and Quarterly Report - March 2020
April 27, 2020
CE Mark for Proteomics PromarkerD Immunoassay Kit
April 15, 2020
Proteomics expands diagnostics R&D - the Promarker Pipeline
April 7, 2020
Proteomics International expands study with US big pharma
March 30, 2020